Aayush Wellness Launches Lung Care Tablets To Enter ₹18,913 Crore Respiratory Healthcare Market

Market snapshot: Aayush Wellness Limited has expanded its preventive healthcare portfolio by launching Lung Care Tablets on August 29, 2026. This launch marks the company's entry into the high-burden Indian respiratory healthcare segment, valued at ₹18,913 crore. The product formulation is specifically designed to address condition-support needs for individuals affected by air pollution, smoking, and environmental stress.

Data Snapshot

• India's respiratory healthcare market size reached ₹18,912.64 crore in 2025, up from ₹17,199.40 crore in 2024.
• India accounts for approximately 30.28% of global deaths caused by respiratory diseases.
• Consolidated sales revenue grew 46.3% YoY to ₹33.11 crore in Q1 FY27 compared to ₹22.63 crore in Q1 FY26.
• Consolidated Net Profit (PAT) for Q1 FY27 expanded 22.6% YoY to ₹1.42 crore from ₹1.16 crore in Q1 FY26.

What's Changed

• Aayush Wellness has systematically expanded its preventive wellness platform from sleep, beauty, and liver care into the high-demand respiratory care segment.
• The underlying respiratory therapeutics market in India grew ≈10% YoY in 2025 (derived: ₹18,912.64 crore in 2025 vs ₹17,199.40 crore in 2024).
• Consolidated financial performance has accelerated, with Q1 FY27 net profits climbing 22.6% YoY to ₹1.42 crore from ₹1.16 crore, driven by a 46.3% YoY revenue jump.

Key Takeaways

• The launch of Lung Care Tablets reflects the company's focus on condition-specific, high-growth OTC nutraceutical categories.
• The product formulation is scientifically backed, incorporating ingredients like N-Acetyl Cysteine, Vasaka Extract, Licorice, Quercetin, Vitamin C, Vitamin D2, and Zinc.
• Strong growth in India's broader $18 billion nutraceutical market supports Aayush Wellness's pivot to high-margin direct-to-consumer health solutions.
• Excellent financial execution, including a 150.8% QoQ consolidated profit surge, provides the capital needed to fuel ongoing retail market expansions.

SAHI Perspective

Aayush Wellness is demonstrating strong execution in its strategic shift from commodity trading to a high-margin, asset-light preventive healthcare model. Entering the respiratory segment with Lung Care Tablets targets a major structural pain point in India—high ambient air pollution and tobacco consumption. The success of this move will depend on retail customer adoption and effective penetration of the OTC consumer healthcare channel, though early financial signals from Q1 FY27 indicate the business model is gaining positive operational momentum.

Market Implications

Entering a specialized condition-support segment could support higher average order values and expand gross margins. By offering a comprehensive preventive care portfolio—spanning herbal masala, sleep, beauty, liver, and lung wellness—Aayush Wellness is building an ecosystem that fosters cross-selling. However, building strong consumer trust in the OTC respiratory space will likely demand consistent marketing investments.

Trading Signals

Market Bias: Bullish

Positive outlook supported by strong Q1 FY27 consolidated revenue growth of 46.3% YoY to ₹33.11 crore, providing solid backing for entering the highly lucrative ₹18,913 crore Indian respiratory market.

Overweight: Preventive Healthcare, Nutraceuticals, FMCG

Trigger Factors:

• Sustained quarterly consolidated revenue growth above 40% YoY in upcoming quarters
• Successful off-take and brand-building of newly launched Lung Care and Liver Detox tablets
• Physical and digital retail network expansion across key urban micro-markets in India

Time Horizon: Medium-term (3-12 months)

Industry Context

India's nutraceutical and preventive healthcare market is estimated at approximately $18 billion, exhibiting robust double-digit growth. The respiratory therapeutic segment specifically recorded sales of ₹18,912.64 crore in 2025. Given that India accounts for over 30% of global deaths from respiratory diseases, there is a clear and growing structural demand for preventative, daily-use condition-support products.

Key Risks to Watch

• Input cost volatility of high-quality herbal and Ayurvedic raw materials could compress margins.
• Heavy competition from established consumer health brands and pharmaceutical conglomerates in the OTC space.
• Regulatory shifts or quality standards implemented by AYUSH or FSSAI requiring additional compliance costs.

Recent Developments

Aayush Wellness launched 'Liver Detox Tablets' on April 24, 2026, targeting the growing lifestyle disease management and liver health market. Additionally, on August 13, 2026, the company reported strong consolidated Q1 FY27 results with a 46% YoY revenue jump to ₹33.11 crore and a 23% PAT rise to ₹1.42 crore.

Closing Insight

Aayush Wellness is demonstrating agile product execution by targeting highly relevant, high-burden healthcare needs. If the company can successfully scale its brand presence alongside its expanding portfolio, this high-margin transition could deliver sustained value for shareholders.

High Performance Trading with SAHI.